S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in
NASDAQ:ARWR

Arrowhead Pharmaceuticals Stock Forecast, Price & News

$85.03
+3.28 (+4.01 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$80.42
Now: $85.03
$85.48
50-Day Range
$74.38
MA: $83.30
$90.47
52-Week Range
$19.51
Now: $85.03
$92.60
Volume687,269 shs
Average Volume822,805 shs
Market Capitalization$8.83 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.62
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals logo

Headlines

ARWR: Multiple Data Readouts in 2021…
February 9, 2021 |  finance.yahoo.com
ARWR Jan 2021 65.000 call
December 31, 2020 |  uk.finance.yahoo.com
ARWR Jan 2021 25.000 put
December 31, 2020 |  uk.finance.yahoo.com
ARWR Feb 2021 105.000 call
December 31, 2020 |  uk.finance.yahoo.com
ARWR Jan 2023 30.000 put
December 31, 2020 |  uk.finance.yahoo.com
ARWR Jun 2021 80.000 put
December 30, 2020 |  uk.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400
Employees232
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$87.99 million
Book Value$4.51 per share

Profitability

Net Income$-84,550,000.00

Miscellaneous

Market Cap$8.83 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.31 out of 5 stars

Medical Sector

688th out of 1,958 stocks

Pharmaceutical Preparations Industry

344th out of 772 stocks

Analyst Opinion: 2.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$85.03
+3.28 (+4.01 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

Is Arrowhead Pharmaceuticals a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arrowhead Pharmaceuticals stock.
View analyst ratings for Arrowhead Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Arrowhead Pharmaceuticals?

Wall Street analysts have given Arrowhead Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arrowhead Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Arrowhead Pharmaceuticals
.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced its quarterly earnings data on Wednesday, February, 3rd. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of $1.00 by $1.20. Arrowhead Pharmaceuticals had a negative net margin of 96.09% and a negative trailing twelve-month return on equity of 17.37%.
View Arrowhead Pharmaceuticals' earnings history
.

How has Arrowhead Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARWR shares have increased by 197.7% and is now trading at $85.03.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ARWR?

13 analysts have issued 12-month price targets for Arrowhead Pharmaceuticals' shares. Their forecasts range from $34.00 to $110.00. On average, they anticipate Arrowhead Pharmaceuticals' stock price to reach $82.43 in the next twelve months. This suggests that the stock has a possible downside of 3.1%.
View analysts' price targets for Arrowhead Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the following people:
  • Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 52, Pay $2.22M)
  • Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 55, Pay $685.85k)
  • Mr. Patrick O'Brien, Gen. Counsel & Corp. Sec. (Age 57, Pay $683.54k)
  • Dr. Bruce D. Given, Advisor (Age 67, Pay $1.35M)
  • Dr. Mark M. Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando
  • Ms. Jane Davidson, Head of HR & Admin., VP and Corp. Sec.
  • Dr. Vincent Anzalone, VP of Investor Relations
  • Mr. Howard Lovy, Director of Communications
  • Dr. James C. Hamilton, Head of Clinical Devel. & VP
  • Dr. Mark Seefeld, Head of Toxicology & VP (Age 67)

Who are some of Arrowhead Pharmaceuticals' key competitors?

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), salesforce.com (CRM) and Advanced Micro Devices (AMD).

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.10%), JPMorgan Chase & Co. (2.32%), Northern Trust Corp (1.50%), Fiera Capital Corp (1.23%), Janus Henderson Group PLC (1.10%) and Bank of New York Mellon Corp (1.00%). Company insiders that own Arrowhead Pharmaceuticals stock include Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien and William D Waddill.
View institutional ownership trends for Arrowhead Pharmaceuticals
.

Which major investors are selling Arrowhead Pharmaceuticals stock?

ARWR stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Capital Impact Advisors LLC, First Trust Advisors LP, Guggenheim Capital LLC, Northern Trust Corp, Barclays PLC, ClariVest Asset Management LLC, and Bank of New York Mellon Corp. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien, and William D Waddill.
View insider buying and selling activity for Arrowhead Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Arrowhead Pharmaceuticals stock?

ARWR stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Western Financial Corporation, Bamco Inc. NY, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Lisanti Capital Growth LLC, Cetera Investment Advisers, and Voloridge Investment Management LLC.
View insider buying and selling activity for Arrowhead Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $85.03.

How much money does Arrowhead Pharmaceuticals make?

Arrowhead Pharmaceuticals has a market capitalization of $8.83 billion and generates $87.99 million in revenue each year. The biotechnology company earns $-84,550,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does Arrowhead Pharmaceuticals have?

Arrowhead Pharmaceuticals employs 232 workers across the globe.

What is Arrowhead Pharmaceuticals' official website?

The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com.

Where are Arrowhead Pharmaceuticals' headquarters?

Arrowhead Pharmaceuticals is headquartered at 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.